Predictive risk factors for distant metastasis in pediatric differentiated thyroid cancer from Saudi Arabia.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2023
Historique:
received: 24 05 2023
accepted: 28 08 2023
medline: 1 11 2023
pubmed: 23 10 2023
entrez: 23 10 2023
Statut: epublish

Résumé

Despite their excellent prognosis, children and young adults (CAYA) with differentiated thyroid cancer (DTC) tend to have more frequent occurrence of distant metastasis (DM) compared to adult DTC. Data about DM in CAYA from Middle Eastern ethnicity is limited. Medical records of 170 patients with DTC ≤18 years were retrospectively reviewed. Clinico-pathological factors associated with lung metastasis in CAYA, their clinical presentation and outcome were analyzed. Rick factors related to distant metastasis-free survival (DMFS) for the whole cohort were evaluated. DM was observed in 27 patients and all were lung metastasis. Lung metastasis was significantly associated with younger age (≤15 years), extrathyroidal extension (ETE), multifocal tumors, bilaterality, presence of lymph node (LN) disease and high post-operative stimulated thyroglobulin (sTg). Highest negative predictive values were seen with low post-operative sTg (97.9%), absence of LN disease (93.8%), absence of ETE (92.2%) and age older than 15 years (92.9%). Post-therapy whole body scan (WBS) identified most of the lung metastasis (21 of 27; 77.8%). Upon evaluating patients response according to ATA guidelines, excellent response was seen in only one patient, while biochemical persistence and structural persistence were seen in 11.1% (3/27) and 77.8% (21/27), respectively. Elevated post-operative sTg (>10ng/ml) was the only risk factor found to be significantly associated with both biochemical persistence (with or without structural persistence (p = 0.0143)) and structural persistence (p = 0.0433). Cox regression analysis identified age and post-operative sTg as independent risk factors related to DMFS. Based on these two risk factors for DMFS, patients were divided into 3 groups: low risk (no risk factors), intermediate risk (1 risk factor) and high risk (both risk factors). 20-year DMFS rates in the low-, intermediate- and high-risk groups were 100.0%, 81.3% and 23.7% respectively (p < 0.0001). Higher suspicion for metastatic pediatric DTC should be considered in patients who are young, have LN disease, extrathyroidal extension and elevated post-operative sTg. Persistent disease, despite therapy, is very common and it appears to be related to post-operative sTg level. Hence, risk adaptive management is desirable in CAYA with DTC.

Sections du résumé

Background
Despite their excellent prognosis, children and young adults (CAYA) with differentiated thyroid cancer (DTC) tend to have more frequent occurrence of distant metastasis (DM) compared to adult DTC. Data about DM in CAYA from Middle Eastern ethnicity is limited.
Methods
Medical records of 170 patients with DTC ≤18 years were retrospectively reviewed. Clinico-pathological factors associated with lung metastasis in CAYA, their clinical presentation and outcome were analyzed. Rick factors related to distant metastasis-free survival (DMFS) for the whole cohort were evaluated.
Results
DM was observed in 27 patients and all were lung metastasis. Lung metastasis was significantly associated with younger age (≤15 years), extrathyroidal extension (ETE), multifocal tumors, bilaterality, presence of lymph node (LN) disease and high post-operative stimulated thyroglobulin (sTg). Highest negative predictive values were seen with low post-operative sTg (97.9%), absence of LN disease (93.8%), absence of ETE (92.2%) and age older than 15 years (92.9%). Post-therapy whole body scan (WBS) identified most of the lung metastasis (21 of 27; 77.8%). Upon evaluating patients response according to ATA guidelines, excellent response was seen in only one patient, while biochemical persistence and structural persistence were seen in 11.1% (3/27) and 77.8% (21/27), respectively. Elevated post-operative sTg (>10ng/ml) was the only risk factor found to be significantly associated with both biochemical persistence (with or without structural persistence (p = 0.0143)) and structural persistence (p = 0.0433). Cox regression analysis identified age and post-operative sTg as independent risk factors related to DMFS. Based on these two risk factors for DMFS, patients were divided into 3 groups: low risk (no risk factors), intermediate risk (1 risk factor) and high risk (both risk factors). 20-year DMFS rates in the low-, intermediate- and high-risk groups were 100.0%, 81.3% and 23.7% respectively (p < 0.0001).
Conclusion
Higher suspicion for metastatic pediatric DTC should be considered in patients who are young, have LN disease, extrathyroidal extension and elevated post-operative sTg. Persistent disease, despite therapy, is very common and it appears to be related to post-operative sTg level. Hence, risk adaptive management is desirable in CAYA with DTC.

Identifiants

pubmed: 37867506
doi: 10.3389/fendo.2023.1228049
pmc: PMC10587684
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1228049

Informations de copyright

Copyright © 2023 Parvathareddy, Siraj, Annaiyappanaidu, Siraj, Al-Rasheed, Al-Haqawi, Qadri, Siddiqui, Al-Sobhi, Al-Dayel and Al-Kuraya.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cancer Genet. 2022 Apr;262-263:57-63
pubmed: 35092884
J Natl Cancer Inst. 2015 Nov 03;108(2):
pubmed: 26538627
Thyroid. 2015 Jul;25(7):716-59
pubmed: 25900731
Int J Cancer. 2016 Sep 1;139(5):1091-7
pubmed: 27082205
Eur J Endocrinol. 2021 Apr;184(4):503-511
pubmed: 33524004
Eur J Nucl Med Mol Imaging. 2015 Jul;42(8):1172-8
pubmed: 25900274
Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1374-1385
pubmed: 34664092
J Clin Endocrinol Metab. 2021 Mar 25;106(4):e1683-e1697
pubmed: 33382403
Pediatr Surg Int. 2016 Mar;32(3):201-8
pubmed: 26717936
J Clin Endocrinol Metab. 2019 Jan 1;104(1):103-110
pubmed: 30272236
Cancer Treat Rev. 2015 Dec;41(10):925-34
pubmed: 26421813
Thyroid. 2010 Oct;20(10):1095-101
pubmed: 20860418
Endocr Connect. 2019 Feb 1;8(2):78-85
pubmed: 30620713
J Clin Oncol. 2022 Apr 1;40(10):1081-1090
pubmed: 35015563
J Clin Endocrinol Metab. 2020 Nov 1;105(11):
pubmed: 32813019
Endocr Rev. 2011 Dec;32(6):798-826
pubmed: 21880704
Endocrine. 2018 Oct;62(1):149-158
pubmed: 30022382
Thyroid. 2021 Jan;31(1):50-60
pubmed: 32517539
J Clin Oncol. 2022 May 1;40(13):1439-1449
pubmed: 35044839
Thyroid. 2010 Apr;20(4):375-80
pubmed: 20373982
Endocr Pract. 2016 Nov;22(11):1259-1266
pubmed: 27482611
Curr Opin Oncol. 2008 Jan;20(1):59-65
pubmed: 18043257
World J Surg. 2018 Feb;42(2):329-342
pubmed: 29030676
CA Cancer J Clin. 2017 Mar;67(2):93-99
pubmed: 28094848
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Surgery. 1988 Dec;104(6):1157-66
pubmed: 3194843
JAMA Otolaryngol Head Neck Surg. 2019 Jul 1;145(7):617-623
pubmed: 31120475
J Clin Endocrinol Metab. 2008 Feb;93(2):611-8
pubmed: 18000091
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Thyroid. 2014 Jul;24(7):1121-6
pubmed: 24731094
J Surg Res. 2009 Sep;156(1):167-72
pubmed: 19631341
Eur J Endocrinol. 2015 Sep;173(3):399-408
pubmed: 26104753

Auteurs

Sandeep Kumar Parvathareddy (SK)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Abdul K Siraj (AK)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Padmanaban Annaiyappanaidu (P)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Nabil Siraj (N)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Maha Al-Rasheed (M)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Wael Al-Haqawi (W)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Zeeshan Qadri (Z)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Khawar Siddiqui (K)

Department of Pediatric Hematology-oncology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Saif S Al-Sobhi (SS)

Department of Surgery, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Fouad Al-Dayel (F)

Department of Pathology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Khawla S Al-Kuraya (KS)

Human Cancer Genomic Research, Research Center, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH